Joint Antiangiogenic Effect of ATN-161 and Anti-VEGF Antibody in a Rat Model of Early Wet Age-Related Macular Degeneration
Authors:
- 9 May 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 13 (9) , 2881-2890
Abstract
The wet form of age-related macular degeneration (AMD) is a leading cause of blindness among elderly Americans and is characterized by abnormal vessel growth, termed choroidal neovascularization (CNV). Integrin α5β1 is a transmembrane receptor that binds matrix macromolecules and proteinases to stimulate angiogenesis. We recently demonstrated that integrin α5β1 plays a critical role in the development of choroidal neovascularization. In this study, we determined the role and underlying mechanisms of integrin α5β1 in angiogenesis in human choroidal endothelial cells and evaluated the antiangiogenic effects of delivering a combination therapy of ATN-161, an integrin α5β1 inhibitor, and an anti-VEGF monoclonal antibody to rats with laser-induced CNV. Vascular endothelial growth factor (VEGF) is a signaling protein that stimulates vasculogenesis and angiogenesis through a pathway that is distinct from the integrin α5β1 signaling pathway. Our results indicate that fibronectin binds to integrin α5β1 and synergizes VEGF-induced angiogenesis via two independent signaling pathways, FN/integrin α5β1/FAK/ERK1/2 and FN/integrin α5β1/FAK/AKT. Integrin α5 knockdown by shRNA inhibits endothelial cell migration, tube formation, and proliferation, while ATN-161 only partially decreases integrin α5 function. Treatment with ATN-161 combined with anti-VEGF antibody showed joint effects in attenuating angiogenesis. In summary, our results provide the first evidence for the mechanisms by which integrin α5β1 is involved in ocular pathological neovascularization in vivo, suggesting that dual inhibition of integrin α5β1 and VEGF may be a promising novel therapeutic strategy for CNV in wet AMD.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2012CB917304, 2014AA021604)
- National Natural Science Foundation of China (81300778, 81425006)
- International Cooperation Project from Science and Technology Commission of Shanghai Municipality (14430721600)
- Shanghai Key Basic Research Grant (11JC141601)
This publication has 30 references indexed in Scilit:
- Intravitreal Aflibercept Injection for Neovascular Age-related Macular DegenerationOphthalmology, 2014
- Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHORBritish Journal of Ophthalmology, 2011
- Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing EyeOphthalmology, 2010
- Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor GrowthClinical Cancer Research, 2008
- Modulation of Hypoxia-Induced Neovascularization by JSM6427, an Integrin α5β 1 Inhibiting MoleculeCurrent Eye Research, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Prevalence of Age-Related Macular Degeneration in the United StatesArchives of Ophthalmology (1950), 2004
- Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE studyOphthalmic Epidemiology, 2004
- Regulation of Angiogenesis in Vivo by Ligation of Integrin α5β1 with the Central Cell-Binding Domain of FibronectinThe American Journal of Pathology, 2000
- Age-Related Macular Degeneration and Blindness due to Neovascular MaculopathyArchives of Ophthalmology (1950), 1984